Post by
Noteable on Jul 06, 2023 11:08am
Pfizer invests in allogeneic CAR-T therapy company
July 06, 2023 - Pfizer purchased 4.6 million shares of Caribou common stock at $5.33 per share in a deal that added up to $25 million and closed June 30.
"Durability is a widespread issue for allogeneic CAR-T developers. In an attempt to tackle CAR-T cell exhaustion and maintain high anti-tumor activity for a longer time, Caribou had removed the PD-1 receptors from its anti-CD19 candidate CB-010. However, last year’s results raise questions about the impact of the work to boost durability.
The relapses overshadowed other, more encouraging aspects of the data, like the 100% complete response rate at the starting dose of 40 million CAR-T cells and no high-grade safety events. "
https://www.fiercebiotech.com/biotech/pfizer-pours-25m-equity-investment-caribous-cell-therapies
[ Dr. Richard Vile of the Mayo Clinic has demonstrated that CAR-T therapy + pelareorep followed by a pelareorep "boost" resulted in CAR=T durability that was determined a "cure" in the animal model ]
Comment by
Noteable on Jul 06, 2023 11:17am
Should read: "... any US government proposals to cap drug prices for drugs developed with federal funds ..."
Comment by
itntdf on Jul 06, 2023 2:24pm
but, could the government cap treatment costs if/when pela is combined with drugs which have been funded in some way by the government like gemcitabine or nab-pax?
Comment by
Noteable on Jul 06, 2023 2:36pm
Nope. Paclitaxel is already a generic drug and combination with this generic will have no impact on pelareorep's pricing.
Comment by
Noteable on Jul 06, 2023 2:48pm
Nor will pricing of pelareorep be impacted by any other drug, generic or not, given that ONCY has self-funded pelareorep's clinical development, or has been supported by a non-profit organization such as PanCan, which has worked to fund the National Cancer Institute.(NCI), rather than the reverse. https://pancan.org/research/increasing-pancreatic-cancer-research-funding/
Comment by
Noteable on Jul 06, 2023 11:22am
Dr. Richard Vile of the Mayo Clinic has demonstrated that CAR-T therapy + pelareorep followed by a pelareorep "boost" resulted in CAR-T durability that was determined a "cure" in the treatment of solid tumors.
Comment by
Noteable on Jul 11, 2023 11:40am
Pfizer purchased 4.6 million shares of Caribou common stock at $5.33 per share in a deal that added up to $25 million and closed June 30.
Comment by
askretka on Jul 15, 2023 5:33pm
Pfizer also has a 25% in off shelf CAR-T company Allogene Therapeutics " Pfizer will hold a 25 percent ownership stake in Allogene Therapeutics https://www.pfizer.com/news/press-release/press-release-detail/pfizer_and_allogene_therapeutics_enter_into_asset_contribution_agreement_for_pfizer_s_allogeneic_car_t_immuno_oncology_portfolio
Comment by
Noteable on Jul 30, 2023 11:29am
The addition of ONCY's pelareorep overcomes CAR-T exhaustion. [ Dr. Richard Vile of the Mayo Clinic has demonstrated that CAR-T therapy + pelareorep followed by a pelareorep "boost" resulted in CAR-T durability that was determined a "cure" in the animal model ]
Comment by
fox7mf on Jul 30, 2023 3:28pm
Perhaps somewhere between $15b-$25b would be more appropriate for all that Oncy & Pela can bring to a BP's bottom line for years to come. My opinion.
Comment by
Buckhenry on Jul 30, 2023 3:50pm
Perhaps... could... maybe... if.... seems like every post from the dreamers section starts with one of these words. I put some numbers on dog biscuits and the first one my dog ate is what I think the company will be sold for. I figure it's as valid as the othe bs I read here.
Comment by
Azzak34 on Jul 30, 2023 4:01pm
Yeah, so.... which one did it eat?
Comment by
Noteable on Jul 30, 2023 5:27pm
Pfizer invested in Caribou with the point being that Pfizer is covering all bases. This perhaps in the use of CAR-T in solid tumors, as it has had success with its CD3-BCMA bispecific anti-body in multiple myeloma, a liquid cancer.
Comment by
Noteable on Oct 05, 2023 6:00pm
ONCY appears to be closely aligned with Pfizer's oncology acquisition and clinical development program given recent news on Pfizer's CD3 bispecific, ADC, CAR-T and current small molecule portfolio (PARP inhibitor), as several examples.
Comment by
jh1970 on Oct 05, 2023 8:42pm
Pfizer invested $25mil at $5.33 per share . After this investment Caribou did financing for $125mil at $6.5 per share which make sense. Why ONC did financing at very low price before partnership agreement not after? Are ONC having problem to have partner ? To many difficult questions .
Comment by
fox7mf on Oct 05, 2023 8:57pm
PFE did blow off Oncy after that sham of the 90 day exclusivity on Bracelet data expired.
Comment by
Noteable on Oct 05, 2023 9:02pm
Pfizer is still in the game with ONCY's pelareorep aligned with multiple Pfizer cancer franchises.
Comment by
Noteable on Oct 05, 2023 9:14pm
Oncy's capital raise was to capitalize on the opportunity presented by PanCan to run a Phase 3 metastatic pancreatic cancer trial under their Precision Promise program. With ONCY correspondingly applying for an ACCELERATED APPROVAL, further leverage on a negotiated acquisition price would putatively result.
Comment by
jh1970 on Oct 05, 2023 9:32pm
Why offering at $2.25 not much higher at $3. We still do not know who bought them. Maybe to cover shorts? To many difficult questions.
Comment by
Lesalpes29 on Oct 06, 2023 6:59am
Money is always good! But again the last PP was a cheap one and since then the SP is stagnant. ONCY seems to always negociate terms in so so position. Now we hope the ph3 in PANC will show good results. A buyout in billions is still a dream or a good running gag! Have great long weekend,